Ovid Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Ami Fadia - Needham & Company - Analyst : Fantastic. Thank you so much for the presentation. Perhaps let's go through some of the assets and maybe I want to get your thoughts on a broader view on the industry. But perhaps just on soticlestat, what's your confidence level with regards to the probability of the trials working? Clearly Takeda seems to have certainly sort of indicated its confidence through the deal, but I wanted your thoughts on -- its studies like (inaudible), but also what is the potential beyond these two indications (inaudible) to study in this trial?

Question: Ami Fadia - Needham & Company - Analyst : Yes, no, I think that makes sense. Could you talk about the possibility of how you would expand utilization beyond these two indications?

Question: Ami Fadia - Needham & Company - Analyst : Let's talk about OV329. Perhaps -- I think this would be -- this is an oral formulation, right, (multiple speakers)?

Question: Ami Fadia - Needham & Company - Analyst : Okay. How would that work in terms of efficacy relative to an injectable? And as you develop it, what are some of the characteristics that you're looking for in the context of a polypharmacy treatment paradigm?

Question: Ami Fadia - Needham & Company - Analyst : Just in terms of next steps, IND filing is expected in 2022. What are some of the next steps or gating factors to get there?

Question: Ami Fadia - Needham & Company - Analyst : Can you help us understand your medium- to long-term strategy around the epilepsy portfolio? Your lead asset you've partnered for commercialization, how do you intend to develop 329 or 350 as they move forward? And would you look to partner them at some point when they reach a later stage of development? Or would you think about taking them forward into commercialization on your own?

Question: Ami Fadia - Needham & Company - Analyst : Perhaps the last question for me, can you talk about just a broad view around over the next 5 to 10 years, how do you see the landscape of epilepsy and the potential for genetically derived medicines? Where do you see this landscape going? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. APRIL 14, 2022 / 4:45PM, OVID.OQ - Ovid Therapeutics Inc at Needham Healthcare Conference (Virtual)

Question: Ami Fadia - Needham & Company - Analyst : Yes, lots of exciting stuff to come. Can't wait. But I think we are out of time. And so, with that I will close the session. Jeremy, thank you so much for the presentation and the talk. And look forward to catching up again soon. And thanks to the listeners for joining in as well.